Natco Pharma aims to diversify product portfolio in domestic market
Informing shareholders, the drug maker said its oncology segment suffered in the last financial year due to pricing controls from the government, and its Hepatitis-C business continued to decline due to reduction in market size.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Cancer & Oncology | Government | Hepatitis | Hepatitis C | Pharmaceuticals